Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CASR | P41180 | 5/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 8/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13294019 | 0.85 | HSD11B1 (0.44) | — | |
| SCHEMBL1407021 | 0.82 | HSD11B1 (0.54) | HTTCNR2CNR1 | |
| SCHEMBL1407130 | 0.81 | POLB (0.45) | POLBCASRTSHRKDM4EALDH1A1 | |
| SCHEMBL1407081 | 0.81 | POLB (0.46) | POLBCASRTSHRKDM4EALDH1A1 | |
| SCHEMBL13294003 | 0.80 | HSD11B1 (0.59) | — | |
| SCHEMBL4720680 | 0.80 | HSD11B1 (0.59) | — | |
| SCHEMBL20108779 | 0.80 | HSD11B1 (0.38) | KDM4EALDH1A1HSD17B10CNR2CNR1 | |
| SCHEMBL13294020 | 0.80 | HSD11B1 (0.43) | — | |
| SCHEMBL1406992 | 0.79 | POLB (0.43) | POLBCASRTSHRKDM4EALDH1A1 | |
| SCHEMBL14413259 | 0.79 | HCRTR1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894054-B2 | FXR agonist compositions for combination therapy | INTERCEPT PHARMACEUTICALS, INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-20180117065-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | INTERCEPT PHARMACEUTICALS, INC. | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894054-B2 | FXR agonist compositions for combination therapy | GPR119, FXR1, NR1H4 | POLB 3923/4885CASR 905/4885TSHR 357/4885 |
| US-20180117065-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | GPR119, FABP1, SLC10A1 | POLB 4039/4885CASR 1725/4885TSHR 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.